You are viewing the site in preview mode
Skip to main content
| |
Cholesterol-low
|
Cholesterol-rich
|
P value
|
|---|
| |
n = 28
|
n = 14
|
|---|
|
Age years (median)
|
63.0
|
67.5
|
0.97
|
|
Tumor size mm (median)
|
22.5
|
20.5
|
0.47
|
|
Tumor grade (NHG)
| | |
0.26
|
|
1
|
7
|
2
| |
|
2
|
12
|
5
| |
|
3
|
9
|
7
| |
|
Mitotic index
| | |
0.10
|
|
1
|
17
|
5
| |
|
2
|
4
|
1
| |
|
3
|
7
|
7
| |
|
ER (n = 31)
| | |
0.31
|
|
Positive
|
21
|
7
| |
|
Negative
|
1
|
2
| |
|
PR (n = 31)
| | |
0.14
|
|
Positive
|
19
|
6
| |
|
Negative
|
3
|
3
| |
|
HER2 (n = 30)
| | |
0.97
|
|
0
|
5
|
2
| |
|
1+
|
7
|
3
| |
|
2+
|
5
|
3
| |
|
3+
|
4
|
1
| |
|
Ki67 index (n = 26)
| | |
0.02*
|
|
Low
|
14
|
1
| |
|
High
|
5
|
6
| |
|
HMGCR (n = 38)
| | |
0.87
|
|
Negative
|
10
|
4
| |
|
Positive
|
16
|
8
| |
|
Serum lipid levels, median (n = 42)
| | | |
|
LDL pre-treatment
|
3.76
|
3.21
|
0.20
|
|
HDL pre-treatment
|
1.60
|
1.41
|
0.54
|
|
Cholesterol pre-treatment
|
6.10
|
5.20
|
0.08
|
|
Apoliporotein B pre-treatment
|
1.07
|
0.91
|
0.11
|
|
Apolipoprotein A1 pre-treatment
|
1.65
|
1.72
|
0.84
|
|
LDL post-treatment
|
1.76
|
1.66
|
0.73
|
|
HDL post-treatment
|
1.58
|
1.51
|
0.56
|
|
Cholesterol post-treatment
|
3.70
|
3.45
|
0.47
|
|
Apolipoprotein B post-treatment
|
0.60
|
0.55
|
0.38
|
|
Apolipoprotein A1 post-treatment
|
1.58
|
1.51
|
0.45
|
- NHG Nottingham histologic grade I-III (post-treatment pathological report), mitotic index according to Nottingham criteria (post-treatment pathological report), baseline tumor data (pretreatment): Ki67 high if > 20%, HMGCR positive if any cytoplasmic staining, ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) P values: Mann Whitney U test, linear-by-linear association chi-square test
